DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD.
Position in JNJ — Johnson & Johnson
CIK 1672142
Singapore, U0
Position in JNJ
as of Jun 30, 2026
· filed Jul 23, 2026
Position Value
$4,647,651
+$1,127,715 QoQ
Shares Held
18,300
+27.1% QoQ
Ownership
0.001%
of shares outstanding
% of Portfolio
0.77%
of 13F equity value
Holder Rank
#1,672
of 4,664 holders
Holding Since
Dec 2020
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026DYMON ASIA CAPITAL (SINGAPORE) PTE. LTD. holds $30,306,066 across 7 Drug Manufacturers - General names. JNJ ranks #3 (15.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | GILD |
Gilead Sciences, Inc.
|
80,000 | $10,107,200 | |
| 2 | AZN |
Astrazeneca PLC
|
30,000 | $5,688,600 | |
| 3 | JNJ |
Johnson & Johnson
This page
|
18,300 | $4,647,651 | |
| 4 | MRK |
Merck & Co., Inc.
|
31,173 | $4,005,730 | |
| 5 | NVS |
Novartis AG
|
16,800 | $2,632,896 | |
| 6 | LLY |
ELI LILLY & Co
|
1,500 | $1,799,145 | |
| 7 | SNY |
Sanofi
|
33,400 | $1,424,844 |
All Filings in JNJ
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $4,647,651 | 18,300 | Shares | Defined | 2026-07-23 | |
| 2026-03-31 | $3,519,936 | 14,400 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $1,024,402 | 4,950 | Shares | Defined | 2026-02-13 | |
| 2025-09-30 | $2,225,040 | 12,000 | Shares | Sole | 2025-11-13 | |
| 2025-06-30 | $2,138,500 | 14,000 | Shares | Defined | 2025-08-14 | |
| 2020-12-31 | $264,870 | 1,683 | Shares | Sole | 2021-02-12 | |
| No filing history on record for this holder in this stock. | ||||||